MTNB Stock - Matinas BioPharma Holdings, Inc.
Unlock GoAI Insights for MTNB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $1.10M | $3.19M | $33,000 | $158,333 |
| Gross Profit | N/A | $1.10M | $-13,490,000 | $-14,550,000 | $-14,200,585 |
| Gross Margin | N/A | 100.0% | -423.1% | -44090.9% | -8968.8% |
| Operating Income | $-24,593,000 | $-23,766,000 | $-24,590,000 | $-24,735,000 | $-24,206,552 |
| Net Income | $-24,251,000 | $-22,942,000 | $-20,997,000 | $-23,283,000 | $-22,446,838 |
| Net Margin | N/A | -2093.2% | -658.6% | -70554.5% | -14177.0% |
| EPS | $-4.98 | $-5.28 | $-3.00 | $-5.04 | $-5.23 |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Visit WebsiteEarnings History & Surprises
MTNBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | — | $-0.40 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-1.03 | — | — |
Q2 2025 | Apr 15, 2025 | $-0.78 | $-1.68 | -115.4% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-0.78 | $-1.50 | -92.3% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-1.05 | $-0.85 | +19.0% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.83 | $-1.00 | -20.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.03 | $-1.50 | -4900.0% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $-1.13 | $-1.50 | -33.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.03 | $-1.50 | -4900.0% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.03 | $-1.50 | -4900.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-1.50 | $-1.50 | 0.0% | = MET |
Q1 2023 | Mar 15, 2023 | $-1.00 | $-1.00 | 0.0% | = MET |
Q4 2022 | Nov 2, 2022 | $-1.50 | $-1.50 | 0.0% | = MET |
Q3 2022 | Aug 11, 2022 | $-1.50 | $-1.50 | 0.0% | = MET |
Q2 2022 | May 12, 2022 | $-1.50 | $-1.50 | 0.0% | = MET |
Q1 2022 | Mar 8, 2022 | $-1.50 | $-1.50 | 0.0% | = MET |
Q4 2021 | Nov 8, 2021 | $-1.50 | $-1.50 | 0.0% | = MET |
Q3 2021 | Aug 10, 2021 | $-1.00 | $-1.00 | 0.0% | = MET |
Q2 2021 | May 10, 2021 | $-1.50 | $-1.50 | 0.0% | = MET |
Frequently Asked Questions about MTNB
What is MTNB's current stock price?
What is the analyst price target for MTNB?
What sector is Matinas BioPharma Holdings, Inc. in?
What is MTNB's market cap?
Does MTNB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MTNB for comparison